TTrialPathMatch Me to Trials
← Back to trials
RecruitingLocalized Prostate CancerBPH (Benign Prostatic Hyperplasia)Prostate Cancer; Benign Prostatic Hyperplasia

Sonablate HIFU International Registry for PC & BPH Patients

Eligible age

18+ yrs

Accepts

Men

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The SONA FUSION Registry is an observational study designed to evaluate the long-term effectiveness and safety of the Sonablate High-Intensity Focused Ultrasound (HIFU) system. This study focuses on adult men who have been treated for localized prostate cancer, benign prostatic hyperplasia (BPH) with urinary symptoms, or a combination of both conditions. The registry collects real-world medical data from multiple clinics globally to better understand how well the HIFU treatment controls disease and affects urinary and sexual function over a 10- to 20-year period. The study includes two groups of participants: a retrospective group of patients who previously received treatment, and a prospective group of newly treated patients receiving standard clinical care. No experimental interventions are assigned for the purpose of this study. To protect participant privacy, all medical data is completely de-identified and stripped of direct identifiers before being securely transferred to the central coordinating center at Indiana University. The ultimate goal of this research is to improve patient care protocols, advance men's health knowledge, and establish evidence-based guidelines for minimally invasive prostate treatments.

Sponsor: Sonablate

You may qualify if…

  • Male with diagnosed localized prostate cancer or BPH (benign prostatic hyperplasia)
  • Having undergone Sonablate HIFU ablation as part of standard clinical care, with all central data transmission subject to a mandatory 180-day post-procedure delay.

You may not qualify if…

  • Prostate size or lesion location precluding effective HIFU target acquisition (prostate volume \>100 CC for prostate cancer or \>80 CC for BPH)
  • Confirmed metastatic prostate cancer
  • Prior radical prostatectomy
  • Prostates with large calcifications (\>10mm causing shadowing)
  • Prior rectal wall surgery or inability to undergo transrectal ultrasound

Where it's recruiting

Indiana

Indianapolis

Source: ClinicalTrials.gov · NCT07757490 · last updated 2026-08-13